Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
>
AstraZeneca reports positive results from phase 3 blood pressure trial
AstraZeneca reports positive results from phase 3 blood pressure trial
Read also
MSD bets big on flu antivirals with $9.2bn buyout of Cidara
MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming patent expiry.
Alembic Pharma gets US FDA
Alembic Pharma gets US FDA approval for angina treatment drug Diltiazem
Scientists uncover new drug target
Scientists uncover new drug target in fight against antimicrobial resistance
General Proximity and Daiichi Sankyo link on oncology
General Proximity has entered a multi-target partnership with Daiichi Sankyo to apply the OmniTAC discovery platform to oncology programmes.
